A Phase 1 interventional study of MK-8507 and Islatravir in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interacti…PubMed 42847999 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main goals of this study are to learn what happens to Islatravir or MK-8507 in a person's body over time. Researchers will compare Islatravir given alone to Islatravir given with MK-8507. Researchers will also compare MK-8507 given alone to MK-8507 given with Islatravir.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants receive single dose of Islatravir on Day 1. Period 2: Participants receive single dose of MK-8507 on Days 1 and Days 8. Period 3: Participants receive single dose of Islatravir and single dose of MK-8507 on Day 1, 7 days after the Day 8 dose of MK-8507, during Period 2. Participants will receive additional MK-8507 single doses on Days 8, 15, 22, and 29.
Drug: MK-8507 · Drug: Islatravir
Oral administration
Oral administration
Also known as: ISL, MK-8591
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Islatravir Metabolite
Blood samples will be collected to determine the AUC0-Inf of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 43 days)
Area Under the Concentration-Time Curve from Time 0 to 168 hours (AUC0-168hrs) of Islatravir Metabolite
Blood samples will be collected to determine the AUC0-168hrs of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 168 hours)
Maximum Concentration (Cmax) of Islatravir Metabolite
Blood samples will be collected to determine Cmax of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 43 days)
Plasma Concentration at 168 Hours (C168) of Islatravir Metabolite
Blood samples will be collected to determine the C168 of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 168 hours)
Time to Maximum Concentration (Tmax) of Islatravir Metabolite
Blood samples will be collected to determine the Tmax of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 43 days)
Apparent Terminal Half-life (t1/2) of Islatravir Metabolite
Blood samples will be collected to determine the t1/2 of Islatravir metabolite.
Time frame: At designated timepoints (up to approximately 43 days)
AUC0-Inf of Islatravir
Blood samples will be collected to determine the AUC0-Inf of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
AUC0-168hrs of Islatravir
Blood samples will be collected to determine the AUC0-168hrs of Islatravir.
Time frame: At designated timepoints (up to approximately 7 days)
Cmax of Islatravir
Blood samples will be collected to determine Cmax of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
C168 of Islatravir
Blood samples will be collected to determine the C168 of Islatravir.
Time frame: At designated timepoints (up to approximately 168 hours)
Tmax of Islatravir
Blood samples will be collected to determine the Tmax of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
t1/2 of Islatravir
Blood samples will be collected to determine the t1/2 of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
Apparent clearance (CL/F) of Islatravir
Blood samples will be collected to determine the CL/F of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
Apparent Volume of Distribution During Terminal Phase (Vd/F) of Islatravir
Blood samples will be collected to determine the Vd/F of Islatravir.
Time frame: At designated timepoints (up to approximately 22 days)
AUC0-168hrs of MK-8507
Blood samples will be collected to determine the AUC0-168hrs of MK-8507.
Time frame: At designated timepoints (up to approximately 7 days)
Cmax of MK-8507
Blood samples will be collected to determine Cmax of MK-8507.
Time frame: At designated timepoints (up to approximately 15 days)
C168 of MK-8507
Blood samples will be collected to determine the C168 of MK-8507.
Time frame: At designated timepoints (up to approximately 168 hours)
Tmax of MK-8507
Blood samples will be collected to determine the Tmax of MK-8507.
Time frame: At designated timepoints (up to approximately 15 days)
t1/2 of MK-8507
Blood samples will be collected to determine the t1/2 of MK-8507.
Time frame: At designated timepoints (up to approximately 15 days)
CL/F of MK-8507
Blood samples will be collected to determine the CL/F of MK-8507.
Time frame: At designated timepoints (up to approximately 15 days)
Vd/F of MK-8507
Blood samples will be collected to determine the Vd/F of MK-8507.
Time frame: At designated timepoints (up to approximately 15 days)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 5 months
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 5 months
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2024 to primary completion in Jun 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interacti…PubMed 42847999 ↗
Nussbaum JC, Pham MM, Vargo R, Liu Y, Triantafyllou I, Boyette N, Matthews RP, Iwamoto M, Gillespie G. Open-label Phase 1 study to evaluate drug-drug interacti…PubMed 42847999 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ulonivirine · Islatravir